Skip to content Skip to sidebar Skip to footer


Five Questions after Amgen v. Sanofi

The Supreme Court’s recent decision in Amgen v. Sanofi puts a spotlight on enablement of functionally defined claims. Future developments may shed light on a number of remaining questions for patent applicants. Here are five areas to watch: 1. What is the impact on other technology? The Court emphasized that “aspects of antibody science remain…

Read More

Enablement Unchanged: Amgen v. Sanofi and the Future of Software Patents | Levenfeld Pearlstein, LLC

In a unanimous ruling, the Supreme Court of the United States (SCOTUS) addressed the enablement requirement under Section 112 of the Patent Act, placing this into sharper focus with the Amgen v. Sanofi case. This landmark decision underlines an essential pillar of patent law, striking a delicate balance between acknowledging the creativity of inventors through…

Read More